Compare KTF & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KTF | SABS |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | United States | United States |
| Employees | N/A | 86 |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 359.6M | 288.8M |
| IPO Year | N/A | N/A |
| Metric | KTF | SABS |
|---|---|---|
| Price | $9.16 | $3.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.75 |
| AVG Volume (30 Days) | 99.4K | ★ 456.5K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 3.54% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.46 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.48 | $1.60 |
| 52 Week High | $9.37 | $6.60 |
| Indicator | KTF | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 59.52 | 40.23 |
| Support Level | $9.13 | $2.84 |
| Resistance Level | $9.26 | $4.09 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 93.33 | 7.93 |
DWS Municipal Income Trust is a closed-ended fixed income mutual fund launched and managed by Deutsche Investment Management Americas, Inc. The company invests in the fixed income markets of the United States. The fund invests in investment-grade tax-exempt municipal securities which are exempt from federal income tax. The fund benchmarks the performance of its portfolio against the Barclays Municipal Bond Index. The Fund invests in various states, such as Texas, Florida, Pennsylvania, Illinois, and California.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.